Other OTC - Delayed Quote USD

Intellipharmaceutics International Inc. (IPCIF)

0.0600 0.0000 (0.00%)
As of April 23 at 3:41 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Isa Odidi MBA, Ph.D. Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer 347.94k -- 1958
Dr. Amina Odidi Ph.D. President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director 347.94k -- 1960
Dr. Patrick N. Yat Ph.D. Vice-President of Chemistry & Analytical Services 119.93k -- 1958
Fazayill Shaideen Controller -- -- --

Intellipharmaceutics International Inc.

30 Worcester Road
Toronto, ON M9W 5X2
Canada
416 798 3001 https://www.intellipharmaceutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
11

Description

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Corporate Governance

Intellipharmaceutics International Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jun 03, 2024 - Jun 07, 2024
Intellipharmaceutics International Inc. Earnings Call

Related Tickers

DRUG.CN Bright Minds Biosciences Inc.
1.6500
0.00%
 
LADX LadRx Corporation
2.2300
+5.19%
 
ENTA Enanta Pharmaceuticals, Inc.
13.06
-0.68%
 
IMUC EOM Pharmaceuticals Holdings, Inc.
0.1979
0.00%
 
XRTX.V XORTX Therapeutics Inc.
3.9500
0.00%
 
RGRX RegeneRx Biopharmaceuticals, Inc.
0.0014
0.00%
 
ADXS Ayala Pharmaceuticals, Inc.
0.5400
0.00%
 
SLGL Sol-Gel Technologies Ltd.
0.9402
-2.19%
 
IUGNF Imugene Limited
0.0500
0.00%
 
HALB Halberd Corporation
0.0080
-2.44%